Learn what lerodalcibep is, how this next-generation PCSK9 inhibitor works, and why its once-monthly dosing and potent LDL-C reduction could transform dyslipidemia and ASCVD management in 2025 and beyond.
Learn what bempedoic acid is, how it works as a non‑statin LDL‑lowering therapy, its liver‑selective mechanism of action, and key clinical evidence from phase 3 and CLEAR Outcomes trials in statin‑intolerant, high‑risk patients.